Our findings strongly suggest that high expression levels of GLUT3 or functionally inactive PRDX1 or both will cause cells to be hypersensitive to arsenite and may serve to identify cancer patients who could benefit from arsenite therapy. The gene discussed is PRDX1; the disease is cancer.